F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Hetero Drugs Ltd. manufactures and markets pharmaceutical ingredients. It manufactures and markets Active Pharmaceutical Ingredients (APIs), intermediate, and finished dosages. The company was founded by Bandi Partha Saradhi Reddy in 1993 and is headquartered in Hyderabad, India.

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It operates through the following segments: Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients. The Domestic Formulations segment operates in the divisions of oncology, pharma specialties and CnD. The International Formulations segment exports its FDF products from India to several international geographies either through its local partners or directly through its subsidiaries such as in Canada and Brazil. The Active Pharmaceutical Ingredients segment is strategically important as it develops APIs for the captive consumption of many of NATCO's critical FDF products in addition to supplying to direct customers. The company was founded by Venkaiah Chowdary Nannapaneni in 1981 and is headquartered in Hyderabad, India.

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Good health and a happy life is something all people rightly aspire to. They believe everyone on the planet deserves access to quality health care. Finding affordable solutions to today's health care challenges demands cutting-edge science, highly talented and motivated people and above all the ability to innovate. Innovation and continuous improvement are the heartbeat of their company. Their mission is to make health care more affordable, increasing access to important medicines through the provision of high quality small molecule generics, and new biological and new chemical entities.

Cerbios specializes in the development and manufacture of chemical and biological APIs. They provide contract development and manufacturing operation services for high-potency active pharmaceutical ingredients, recombinant proteins, and antibody drug conjugates, from preclinical to commercial supply. They also provide drug substances, animal health, and drug products.

Zhejiang Huahai Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products. It also integrates and intermediates formulations such as Active Pharmaceutical Ingredients. Its products include Irbesartan and Hydrochlorothiazide Tablet, Paroxetine Hydrochloride Tablet and Irbesartan Tablet. The company was founded in 1989 and is headquartered in Zhejiang, China.

Shandong Jincheng Pharmaceutical Group Co., Ltd. engages in the research and development, production and sale of III and IV cephalosporin intermediates and bio-pharmaceuticals. Its products are categorized into the following divisions: Characteristic Bulk Drugs, Pharmaceutical Intermediates, and Fine Chemicals. The company was founded by Hong Fu Zhao on January 12, 2004 and is headquartered in Zibo, China.

Laurus labs is an innovation-driven¸ people-centric & client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry. Equipped with a world-class infrastructure manned by best-in-class personnel & driven by the core values of knowledge, innovation and excellence, within a relatively short period, Laurus labs emerged as a segment-leading manufacturer of high quality APIs, a preferred partner for NCE development & manufacture & a trusted source of specialty ingredients for the nutraceutical industry. Given the strengths, capabilities & experience, Laurus Labs is uniquely positioned to help its clients in their endeavor of ‘quicker to market’ & thus contributing towards improving access to quality & affordable healthcare worldwide.

Nippon Kayaku produces and retails a range of chemicals. By product category, the company divides itself into four areas. Epoxy resins used as flame retardants in electronics, colorants, and dyes used in inkjet printers and materials for the production of textiles are sold by the functional chemicals segment, which is the one that generates the most income of any segment. Pharmaceutical companies market anti-cancer, biological, cardiovascular, vitamin, and anti-inflammatory medications. The automotive sector is supplied by the safety systems segment with airbag inflators and micro gas generators for seatbelt pre-tensioners, both of which are intended to protect passengers in the event of an accident. Insecticides and herbicides are offered for sale in the agrochemicals market.

Part of Hansoh Pharmaceutical Group Co., Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd. is a company headquartered in Jiangsu, China, that manufactures and distributes pharmaceutical products.

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical products and wind power generation. The company was founded on November 20, 1987 and is headquartered in Raichur, India.

Remedica is based in Limassol, Cyprus and is the leading pharmaceutical company in the country dedicated to the development, production and sale of high quality generic pharmaceutical products. These fall into a wide range of therapeutic categories (such as anticancer, antibiotics, analgesics, cardiovascular drugs, CNS agents, drugs for the GI tract, diuretics, antihistamines, antidiabetics, antiparkinsonian agents, hormones and synthetic substitutes, vitamins, cough medicines and expectorants, and many more) and come in a variety of pharmaceutical dosage forms, including tablets, capsules, creams, ointments, aerosols, pessaries, suppositories, liquids, powders. Remedica’s products circulate in more than one hundred countries worldwide through a selective network of representatives and some are also available for in-licensing by other companies.

Generics (U.K.) Ltd. manufactures generic pharmaceutical products. It makes generic drugs which includes acid reflux remedy Pepcid, antibiotic Cipro and allergy treatment Zyrtec. The firm also manufactures cytotoxics such as azathioprine and penicillin based antibiotics. The company was founded on April 29, 1981 and is headquartered in Potters Bar, the United Kingdom.

Chongqing Huapont Pharmaceutical Co. Ltd., part of Huapont Life Sciences Co., Ltd., is a company headquartered in Chongqing, China. The firm manufactures pharmaceutical products.

Chongqing Huabang Shengkai Pharmaceutical Co., Ltd., established on 2009-08-28, Business scope includes licensed projects:pharmaceutical production;Drug import and export;Pharmaceutical commissioned production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Medical Research and Experimental Development;Chemical product sales(No licensed chemical products);Manufacturing of basic chemical raw materials(Manufacture of licensed chemicals free of hazardous chemicals).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shandong Yuxin Pharmaceutical Co., Ltd., established on 2010-12-30, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;Drug retail;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Disinfectant production(Free of Hazardous Chemicals);Catering Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Pharmaceutical commissioned production;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Production of labor protection products;Sales of labor protection products;Disinfectant sales(Free of Hazardous Chemicals);Medical Research and Experimental Development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Part of Chengdu Giantech Hi-Technology Development Co., Ltd., Chengdu Sino-Strong Pharmaceutical Co. Ltd. is a Chinese company. The firm develops and manufactures pharmaceuticals.

Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd., established on 2011-04-11, The business scope includes Chinese and Western medicines,Development of pharmaceutical raw materials,to develop;API,Antitumor raw materials,Sterile API,Chemical raw materials for pharmaceutical production,Production of excipients and intermediates,Sales(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).